SYRS: רווח למניה בשנים עשר החודשים האחרונים syros.com

Scientific interest in cancer therapy innovations supports the rolling earnings per share trend on the GURU.Markets terminal chart, where the -3.10 mark reflects the latest data for Syros Pharmaceuticals (SYRS). However, capital has been depleted due to clinical failures, and management is seeking buyers for patents to settle debts amid a rigorous restructuring.

Syros Pharmaceuticals (SYRS) focuses on developing high-precision drugs to manage gene expression in oncology. This indicator measures the total earnings per common share over the last four quarters. By analyzing the rolling net income per share, an investor can gauge the actual efficiency of monetizing the scientific base. The curve's trend allows for the rapid detection of liquidity shortages or margin compression, which is critical for assessing the company's capital stability.